JP2015537190A - 低減された免疫原性を有する抗体を同定するための方法 - Google Patents

低減された免疫原性を有する抗体を同定するための方法 Download PDF

Info

Publication number
JP2015537190A
JP2015537190A JP2015533163A JP2015533163A JP2015537190A JP 2015537190 A JP2015537190 A JP 2015537190A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015537190 A JP2015537190 A JP 2015537190A
Authority
JP
Japan
Prior art keywords
cdr
antibody
tnf
variant
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015533163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537190A5 (cg-RX-API-DMAC7.html
Inventor
フィオナ エイ． ハーディング
フィオナ エイ． ハーディング
オリビア ジェニファー ラゾ
オリビア ジェニファー ラゾ
Original Assignee
アッヴィ・バイオセラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・バイオセラピューティクス・インコーポレイテッド filed Critical アッヴィ・バイオセラピューティクス・インコーポレイテッド
Publication of JP2015537190A publication Critical patent/JP2015537190A/ja
Publication of JP2015537190A5 publication Critical patent/JP2015537190A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015533163A 2012-09-19 2013-09-18 低減された免疫原性を有する抗体を同定するための方法 Pending JP2015537190A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
US61/703,170 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (2)

Publication Number Publication Date
JP2015537190A true JP2015537190A (ja) 2015-12-24
JP2015537190A5 JP2015537190A5 (cg-RX-API-DMAC7.html) 2016-11-04

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533163A Pending JP2015537190A (ja) 2012-09-19 2013-09-18 低減された免疫原性を有する抗体を同定するための方法

Country Status (27)

Country Link
US (1) US9279016B2 (cg-RX-API-DMAC7.html)
EP (2) EP2897978B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015537190A (cg-RX-API-DMAC7.html)
KR (1) KR20150056788A (cg-RX-API-DMAC7.html)
CN (1) CN104704000A (cg-RX-API-DMAC7.html)
AU (1) AU2013318147B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015005857A2 (cg-RX-API-DMAC7.html)
CA (1) CA2885422A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118893T1 (cg-RX-API-DMAC7.html)
DK (1) DK2897978T3 (cg-RX-API-DMAC7.html)
ES (1) ES2621285T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170937T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032569T2 (cg-RX-API-DMAC7.html)
IL (1) IL237833A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01967A (cg-RX-API-DMAC7.html)
LT (1) LT2897978T (cg-RX-API-DMAC7.html)
MX (1) MX2015003541A (cg-RX-API-DMAC7.html)
NZ (1) NZ705606A (cg-RX-API-DMAC7.html)
PL (1) PL2897978T3 (cg-RX-API-DMAC7.html)
PT (1) PT2897978T (cg-RX-API-DMAC7.html)
RS (1) RS56093B1 (cg-RX-API-DMAC7.html)
RU (1) RU2648141C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201502094TA (cg-RX-API-DMAC7.html)
SI (1) SI2897978T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700255T1 (cg-RX-API-DMAC7.html)
TW (1) TWI519646B (cg-RX-API-DMAC7.html)
WO (1) WO2014047222A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN118497192A (zh) * 2017-03-07 2024-08-16 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
TW202039554A (zh) * 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
EP4037699A1 (en) 2019-09-30 2022-08-10 SciRhom GmbH Protein binders to irhom2 epitopes
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
WO2022184594A1 (en) 2021-03-01 2022-09-09 Scirhom Gmbh Humanized antibodies against irhom2
CA3213771A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
KR20250049549A (ko) 2022-08-08 2025-04-11 에이티비 테라퓨틱스 CD79b에 대한 인간화된 항체
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507810A (ja) * 1996-02-09 2000-06-27 ベーアーエスエフ アクツィエンゲゼルシャフト ヒトＴＮＦαに結合するヒト抗体
WO2010142990A1 (en) * 2009-06-09 2010-12-16 Affitech Research As ANTI-EpCAM ANTIBODIES
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012020038A1 (en) * 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DE3687170T2 (de) 1985-01-25 1993-04-01 Kitasato Inst Antitumorale antibiotika und deren herstellung.
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
EP1218543A2 (en) 1999-09-29 2002-07-03 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002027029A2 (en) 2000-09-27 2002-04-04 Lynx Therapeutics, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AU2003283995A1 (en) 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
ATE461220T1 (de) 2005-11-12 2010-04-15 Lilly Co Eli Anti-egfr-antikörper
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507810A (ja) * 1996-02-09 2000-06-27 ベーアーエスエフ アクツィエンゲゼルシャフト ヒトＴＮＦαに結合するヒト抗体
WO2010142990A1 (en) * 2009-06-09 2010-12-16 Affitech Research As ANTI-EpCAM ANTIBODIES
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012020038A1 (en) * 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies

Also Published As

Publication number Publication date
CY1118893T1 (el) 2018-01-10
BR112015005857A2 (pt) 2017-08-08
WO2014047222A3 (en) 2014-10-23
PT2897978T (pt) 2017-05-22
RS56093B1 (sr) 2017-10-31
EP3211006A2 (en) 2017-08-30
SG11201502094TA (en) 2015-04-29
RU2648141C2 (ru) 2018-03-22
SMT201700255T1 (it) 2017-07-18
TWI519646B (zh) 2016-02-01
MX2015003541A (es) 2015-10-26
EP2897978A2 (en) 2015-07-29
CA2885422A1 (en) 2014-03-27
SI2897978T1 (sl) 2017-05-31
NZ705606A (en) 2018-05-25
HRP20170937T1 (hr) 2017-11-03
KR20150056788A (ko) 2015-05-27
CN104704000A (zh) 2015-06-10
AU2013318147B2 (en) 2018-01-04
WO2014047222A9 (en) 2014-06-26
IN2015DN01967A (cg-RX-API-DMAC7.html) 2015-08-14
US9279016B2 (en) 2016-03-08
ES2621285T3 (es) 2017-07-03
RU2015111671A (ru) 2016-11-10
LT2897978T (lt) 2017-06-12
PL2897978T3 (pl) 2017-08-31
EP3211006A3 (en) 2017-11-08
HK1211306A1 (en) 2016-05-20
AU2013318147A1 (en) 2015-03-19
EP2897978B1 (en) 2017-03-22
IL237833A0 (en) 2015-05-31
WO2014047222A2 (en) 2014-03-27
DK2897978T3 (en) 2017-05-15
TW201418469A (zh) 2014-05-16
HUE032569T2 (en) 2017-09-28
US20140227251A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
EP2897978B1 (en) Methods for identifying antibodies with reduced immunogenicity
US9315573B2 (en) Anti-TNF-alpha antibodies and their uses
JP5859202B2 (ja) 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
CN105377892A (zh) 抗cd25抗体及其用途
WO2018202200A1 (en) Anti-interferon gamma antibodies and uses thereof
CN105121470A (zh) 抗cd25抗体及其用途
CA2938931A1 (en) Anti-laminin4 antibodies specific for lg1-3
HK1211306B (en) Methods for identifying antibodies with reduced immunogenicity
HK1205149A1 (en) Target-tissue-specific antigen-binding molecule

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180905